Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Moderna Q1 earnings, revenue surprisingly tops consensus estimates

Published 05/04/2023, 10:04 PM
Updated 05/04/2023, 10:04 PM
© Reuters

© Reuters

Moderna (NASDAQ:MRNA) shares opened higher Thursday on the back of its surprising earnings and revenue beat.

The drugmaker had been expected to post a $1.75 loss in the quarter, however, it reported Q1 EPS of $0.19, topping expectations by $1.94. In addition, revenue for the quarter came in at $1.9 billion, above the consensus estimate of $1.18 billion.

Despite the demand for COVID vaccines being significantly lower, the company said it was encouraged by the progress of new COVID-19 vaccine contracts in the U.S. for this fall with pharmacy chains, hospital networks, and multiple U.S. government agencies.

In addition, $1.8B in sales represents the vast majority of the projected $2B in sales from 2022 deferrals expected in the first half of 2023.

Moderna shares are currently trading 2% higher.

"We had a strong first quarter, with $1.9 billion in revenue, clearly indicating that we are on our way to deliver on the $5 billion of signed Advance Purchase Agreements for 2023," said Stéphane Bancel, chief executive officer of Moderna.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.